LCM
KALA icon

Laurion Capital Management’s KALA BIO KALA Stock Holding History

Laurion Capital Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-80
Closed -$4.57M – 1679
2017
Q3 		$4.57M Buy
+80
New +$4.39M 0.02% 530

Other funds holding KALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Laurion Capital Management's KALA Position: Q4 2017 in Review

Laurion Capital Management sold out of KALA BIO (KALA) in Q4 2017, closing a stake of 80 shares — an estimated $4.57M sold.

Laurion Capital Management first reported a position in KALA in Q3 2017 and held it in 1 quarter. The position peaked at $4.57M in Q3 2017. 54 funds tracked by Wall St. Rank hold KALA as of Q4 2017.

  • Laurion Capital Management reported no remaining KALA BIO position as of Q4 2017 after selling out during the quarter.
  • Laurion Capital Management sold 80 KALA BIO shares in Q4 2017, an estimated $4.57M.
  • Laurion Capital Management first reported a position in KALA BIO in Q3 2017 and held it in 1 quarter.
  • Laurion Capital Management's KALA BIO position peaked at $4.57M in Q3 2017.
  • 54 funds tracked by Wall St. Rank held KALA BIO as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.